MYD88 and osteosarcoma: The rationale for focusing on CD36 and MYD88 as therapeutic targets is underpinned by studies that demonstrate their involvement in tumorigenic processes and their specific impact on inflammasome regulation, which can significantly influence the progression and aggression of osteosarcoma.